Developmental FGFR Inhibitors Are Active in FGFR+ Cholangiocarcinoma and Urothelial Carcinoma
January 6th 2023Mitesh J. Borad, MD, explains how FGFR alterations influence treatment strategies in cholangiocarcinoma and urothelial cancer, discusses the FGFR resistance mechanisms that are prompting further research in this area, and highlights the rationale for the KN-4802 trial.
Resistance Mechanisms Spur Innovative Research in FGFR-Mutant Liver and Bladder Cancer
December 7th 2022Sameek Roychowdhury, MD, PhD, discusses the rationale for targeting FGFR mutations in cholangiocarcinoma and urothelial carcinoma, the potential efficacy of irreversible pan-FGFR inhibitors in these populations, and how continued research in this area may yield more personalized therapeutic approaches for patients with FGFR mutations.